Discount program, second order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy DOC for sale
In recent years, DOC, known as 2,5-Dimethoxy-4-chlorophenethylamine, has become a psychoactive chemical. It is linked to the phenethylamine 3,4-Methylenedioxy-N-methylamphetamine (MDMA or "ecstasy") and the stimulant methamphetamine and was initially synthesized by the renowned scientist Alexander Shulgin. The substance is categorized as a member of the broader category of designer pharmaceuticals, chemically modified variants of existing medications.
Although DOC is not as well-known as other designer drugs, such as ecstasy or methamphetamine, its potential for damage makes it a substance of concern. This essay will examine the history, effects, and risks associated with DOC to offer a thorough knowledge of this psychoactive chemical.
History of DOC
Alexander Shulgin initially synthesized DOC in the late 1960s. Shulgin was a prominent scientist who devoted his career to studying the impact of psychoactive drugs on the human body. It is widely acknowledged that he pioneered the research of designer medications, and his contributions continue to impact the subject.
Shulgin did not confine his studies with DOC and other psychoactive chemicals to the laboratory; he also experimented with them to better understand their effects. This method enabled him to obtain more profound knowledge of these compounds and give valuable insights into their possible risks.
Effects of DOC
DOC is a potent psychoactive chemical that may affect a person's perception, thoughts, and emotions. The effects of DOC can be unexpected and highly variable according to dosage, individual tolerance, and route of administration.
At lesser dosages, DOC can cause modest stimulant effects and boost a person's alertness and vitality. However, the effects may become more severe and potentially harmful with greater dosages. Visual and auditory hallucinations, altered perceptions of time and space, and a strong sense of detachment from reality are some consequences of excessive dosages of DOC.
Additionally, DOC can induce feelings of exhilaration and promote sociability. However, these benefits can be temporary and frequently result in worry and paranoia, especially if the individual has an unfavourable reaction to the drug.
Dangers of DOC
DOC is a solid psychoactive chemical that can generate various physical and psychological side effects. Cardiovascular issues, such as an elevated heart rate and blood pressure, as well as the possibility of convulsions and coma, are among the most prominent hazards linked with DOC usage.
In addition to its physical hazards, DOC may also significantly impact an individual's mental health. Severe anxiety, paranoia, and a profound sense of detachment from reality can result from the intense hallucinations and changed perceptions of reality that can occur with large dosages of DOC. This can have long-term impacts on a person's mental health and contribute to the development of mental health issues.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics